The purpose of this commentary is to provide information on the present status of the racemate/enantiomer debate in Japan and current industrial and regulatory attitudes to chiral drugs in Japan. It provides an update of our previous paper (Shindo and Caldwell, Chirality 3:91–93, 1991), and the interested reader is referred to this for background information.
No takes yet. Share an insight, caveat, or question.
SHINDO et al. (1995) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: